Centre Hospitalier Regional Universitaire — Clinical Trial Site

33 Registered trials

18 Currently recruiting

Organisation

Centre Hospitalier Regional Universitaire

Location

Besancon Cedex, France

Identifier

ORG-100008647

Address

2 Place Saint Jacques, Cs 51804, 25030, France

Departments

Département de radiothérapie
Départment D'Oncologie Médicale
Dermatologie
Dermatology
DIGESTIF
Endocrinologie-diabétologie
Hématologie
Hematology
INFECTIOLOGIE
Medical oncologist
Neurology
Oncologie
Oncologie médicale
Oncology
pediatrie oncologie hematologie
Pneumologie
pneumology
Pneumonology
Service de Maladies infectieuses
Service Oncologie
Urgences
Urologie

Clinical trials at this site (33)

Search interface

SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Medulloblastoma 10
EVALUATION OF UCPVAX VACCINE +/- PEMBROLIZUMAB COMBINED WITH STANDARD TREATMENT AS ADJUVANT THERAPY IN PATIENTS WITH UNMETHYLATED GLIOBLASTO… Pending

2024-514399-42-00 Glioblastoma 4
NEOSTART Study - NEOADJUVANT PEMBROLIZUMAB IN PATIENTS WITH HIGH RISK, STAGE IIB/IIC CUTANEOUS MELANOMA: A SINGLE ARM PROOF OF CONCEPT PHASE… Pending

2024-519573-19-00 melanoma 4
RIFAMAB : Rifabutin versus rifampicin, staphylococcal prosthetic joint infection, multicenter randomized, open-label, non-inferiority trial Pending

2024-519894-20-01 Adult with an staphylococcal prosthetic joint infection 5
GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE ADMITTED IN THE EMERGENCY … Pending

2025-521101-40-00 CHRONIC DECOMPENSATED HEART FAILURE 6
Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial Recruiting

2024-514799-42-00 IDIOPATHIC PULMONARY FIBROSIS 4 2024-11-05
CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al… Recruiting

2024-517004-11-00 Chronic pulmonary aspergillosis 5 2024-10-22
ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc… Recruiting

2023-505486-92-00 Small bowel adenocarcinoma 4 2024-02-09
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
TACTIC : MP0317, A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN, IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PAT… Recruiting

2024-520029-35-01 ADVANCED BILIARY TRACT CARCINOMA 4 2025-11-17
Immunogenicity and safety of the 20-Valent pneumococcal conjugate vaccine (PCV-20) administered during an acute febrile illness in adults Recruiting

2024-517411-73-00 Patient with medium or high risk for pneumococcal invas 6 2025-11-12
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemoth… Recruiting

2024-516709-22-00 metastatic colorectal cancer carcinoma 10 2024-12-16
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Patients with pMMR/MSS metastatic adenocarcinoma of the 4 2024-12-10
TOLEDDO: Effect of weekly GLP1 agonist treatment in "double diabetes": a randomized, open-label study Recruiting

2024-514906-30-00 "double diabetes" 5 2024-10-14
TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis (TOTEM-RRMS) Recruiting

2024-517845-14-00 Relapsing Remitting Multiple sclerosis 4 2024-10-03
Ezabenlimab (BI 754091) and DCFm (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy for the treatment of stage III anal… Recruiting

2024-514083-31-00 squamous cell anal carcinoma 4 2024-07-26
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o… Recruiting

2023-509761-21-00 Metastatic colorectal cancer 5 2024-07-08
PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 colon carcinoma 5 2024-06-07
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Peripheral T-cell lymphoma (PTCL) 6 2023-06-07
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting

2023-508302-24-00 Locally Advanced/Metastatic Urothelial Cancer 4 2019-05-07
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26